RU2019116069A - Новые биомаркеры старения кожи человека - Google Patents

Новые биомаркеры старения кожи человека Download PDF

Info

Publication number
RU2019116069A
RU2019116069A RU2019116069A RU2019116069A RU2019116069A RU 2019116069 A RU2019116069 A RU 2019116069A RU 2019116069 A RU2019116069 A RU 2019116069A RU 2019116069 A RU2019116069 A RU 2019116069A RU 2019116069 A RU2019116069 A RU 2019116069A
Authority
RU
Russia
Prior art keywords
expression level
skin
hmgn1
tubb3
hmga2
Prior art date
Application number
RU2019116069A
Other languages
English (en)
Russian (ru)
Inventor
Сандрин БУРГУЭН-ВУАЙАР
Сильвия Мари-Луиз ЛЕМАНН
Валид РАШИДИ
Мишель СЕВ
Original Assignee
Юниверсите Гренобль Альп
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсите Гренобль Альп filed Critical Юниверсите Гренобль Альп
Publication of RU2019116069A publication Critical patent/RU2019116069A/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Cosmetics (AREA)
RU2019116069A 2016-11-25 2017-11-24 Новые биомаркеры старения кожи человека RU2019116069A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16306561.8 2016-11-25
EP16306561 2016-11-25
PCT/EP2017/080414 WO2018096117A1 (en) 2016-11-25 2017-11-24 New biomarkers of human skin aging

Publications (1)

Publication Number Publication Date
RU2019116069A true RU2019116069A (ru) 2020-12-25

Family

ID=57517827

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019116069A RU2019116069A (ru) 2016-11-25 2017-11-24 Новые биомаркеры старения кожи человека

Country Status (7)

Country Link
US (1) US20210109111A1 (enExample)
EP (1) EP3545301A1 (enExample)
JP (1) JP7115756B2 (enExample)
CN (1) CN110268263B (enExample)
CA (1) CA3041959A1 (enExample)
RU (1) RU2019116069A (enExample)
WO (1) WO2018096117A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019236632A1 (en) * 2018-06-04 2019-12-12 Avon Products. Inc. Protein biomarkers for identifying and treating aging skin and skin conditions
JP7633003B2 (ja) * 2019-11-29 2025-02-19 ポーラ化成工業株式会社 抗老化成分のスクリーニング方法
WO2023090901A1 (ko) * 2021-11-18 2023-05-25 의료법인 성광의료재단 기계 학습을 이용한 세포 노화의 마커를 선별하는 방법, 세포 노화 바이오 마커, 및 이를 이용한 세놀리틱 제제를 스크리닝 하는 방법
EP4460493A4 (en) 2022-01-07 2025-12-31 Oddity Labs Llc SKIN COMPOSITIONS, FORMULATIONS AND PROCESSES
JP7877021B2 (ja) * 2022-03-08 2026-06-22 株式会社 資生堂 黄ぐすみ抑制方法、黄ぐすみ抑制剤のスクリーニング方法、及び黄ぐすみ感受性の評価方法
JP7896869B2 (ja) * 2022-08-30 2026-07-29 日本メナード化粧品株式会社 皮膚弾力性のマーカー及びその利用
KR20260020360A (ko) * 2024-08-01 2026-02-11 고려대학교 산학협력단 Hmgb1를 포함하는 노화 진단 또는 유도용 바이오마커 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001249098A1 (en) * 2000-03-10 2001-09-24 Lifespan Biosciences, Inc. Nucleic acid sequences associated with aging, particularly skin aging
DE10100121A1 (de) * 2001-01-03 2002-08-01 Henkel Kgaa Verfahren zur Bestimmung des Hautstreß oder der Hautalterung in vitro
EP1579221A2 (de) * 2003-01-03 2005-09-28 Alcedo Biotech GmbH Verwendungen von hmgb, hmgn, hmga proteinen
WO2004083398A2 (en) * 2003-03-17 2004-09-30 The Government Of The United States Of America As Represented By The Secretary Of Department Of Health And Human Services Therapeutic uses of hmgn1 and hmgn2
US7972788B2 (en) * 2005-08-23 2011-07-05 Fancl Corporation Skin aging marker and technique for use thereof
US8859021B2 (en) * 2007-05-14 2014-10-14 Sytheon Skin appearance through gene manipulation
KR100999261B1 (ko) * 2007-10-09 2010-12-07 (주)아모레퍼시픽 여성호르몬 결핍으로 초래되는 여성 피부의 노화 억제제 스크리닝 방법
FR2925313A1 (fr) * 2007-12-19 2009-06-26 Oreal Utilisation cosmetique de proteines de type plakoglobine
US20120034613A1 (en) * 2010-08-03 2012-02-09 Nse Products, Inc. Apparatus and Method for Testing Relationships Between Gene Expression and Physical Appearance of Skin
EP2704728A4 (en) * 2011-05-03 2015-04-22 Dermachip Inc EXPRESSION SIGNATURES OF AGENTS ASSOCIATED WITH SKIN AGING AND GEN NETWORKS
JP6336565B2 (ja) * 2013-03-15 2018-06-06 ザ プロクター アンド ギャンブル カンパニー 微生物からの自然防御の客観的尺度として皮膚から抗微生物ペプチドを測定するための非侵襲的方法

Also Published As

Publication number Publication date
US20210109111A1 (en) 2021-04-15
WO2018096117A1 (en) 2018-05-31
EP3545301A1 (en) 2019-10-02
CA3041959A1 (en) 2018-05-31
CN110268263B (zh) 2022-07-19
JP2020502498A (ja) 2020-01-23
CN110268263A (zh) 2019-09-20
JP7115756B2 (ja) 2022-08-09

Similar Documents

Publication Publication Date Title
JP2020502498A5 (enExample)
Tao et al. Pitx2 promotes heart repair by activating the antioxidant response after cardiac injury
RU2012125253A (ru) Система для увеличения экспрессии генов и вектор, содержащий указанную систему
Barreto et al. Effects of heat shock protein 72 (Hsp72) on evolution of astrocyte activation following stroke in the mouse
JP2014521308A5 (enExample)
JP7390002B2 (ja) 頭頸部がんの検出を補助する方法
EP4276194A3 (en) Methods and processes for non-invasive assessment of genetic variations
CN108701173A (zh) 用于发现预测对检查点抑制剂敏感的msi和新表位的系统、组合物和方法
US12618097B2 (en) Method for determining long non-coding ribonucleic acid interaction proteins
JP2016507233A5 (enExample)
Frade et al. Polymorphism in the alpha cardiac muscle actin 1 gene is associated to susceptibility to chronic inflammatory cardiomyopathy
Li et al. Multi-species meta-analysis identifies transcriptional signatures associated with cardiac endothelial responses in the ischaemic heart
Gao et al. BZW2 gene knockdown induces cell growth inhibition, G1 arrest and apoptosis in muscle‐invasive bladder cancers: A microarray pathway analysis
Lin et al. Acute dyskerin depletion triggers cellular senescence and renders osteosarcoma cells resistant to genotoxic stress-induced apoptosis
RU2012103932A (ru) Биомаркер для отбора пациентов и связанные с ним способы
Mika et al. Transposable elements continuously remodel the regulatory landscape, transcriptome, and function of decidual stromal cells
Hao et al. Neuregulin-1β induces embryonic stem cell cardiomyogenesis via ErbB3/ErbB2 receptors
Lu et al. A functional polymorphism in interleukin-1α (IL1A) gene is associated with risk of alopecia areata in Chinese populations
Dhaeze et al. Sex-dependent factors encoded in the immune compartment dictate relapsing or progressive phenotype in demyelinating disease
Yang et al. Elevated serum haptoglobin after traumatic brain injury is synthesized mainly in liver
Liu et al. Regulation of heart regeneration by LSD1 through suppressing CEND1
CN106222242A (zh) 长链非编码rna-apoc1p1-3基因及其在用于制备靶点标志物中的用途
Xiaodi et al. DNA methylation at CpG island shore and RXRα regulate NR2F2 in heart tissues of tetralogy of Fallot patients
US20240082290A1 (en) Strategy to increase anti-viral, anti-microbial, and anti-fungal defense
JP2012170335A (ja) 口腔扁平上皮癌の診断方法及び治療用組成物

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20201125